Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2012

View Archived Issues

Novel agents for migraine prepared at Merck & Co.

Jenrin Discovery designs novel compounds targeting the cannabinoid CB1 receptor

Pilot study evaluates iobenguane (131I) in newly diagnosed high-risk neuroblastoma

Novel anticancer TLR7 agonists disclosed

New agents for pulmonary hypertension presented by Ironwood Pharmaceuticals

Celgene patents novel inhibitors of mutant EGFR

U.S. researchers disclose novel metalloenzyme inhibitors

New antisense oligonucleotides designed at Japanese university

Instituto Biomar reports new agents from a marine microorganism

Novel prognostic marker for cervical cancer correlates with EGFR expression

Gilead characterizes bifunctional LABA/PDE4 inhibitor

Data from expanded moxetumomab trial support further testing

Phase I/II trial evaluates KW-2871 combination therapy in melanoma

Newron announces acquisition plan

JDRF and Novo Nordisk establish type 1 diabetes partnership

Upsher-Smith to acquire European biotechnology company

FDA grants orphan drug status to new Regenicin product

Azaya Therapeutics reports phase I liposomal docetaxel data

EMA's COMP issues opinion on Enhoxy

Biofrontera to pursue U.S. registration of Ameluz

Ophthotech reports results from Fovista/Lucentis study

Janssen clear to take FGFR kinase inhibitor into phase I trials

Kuros reports promising results on novel dural sealant

New SBIR grant supports malaria research at Sanaria and IBBR

SymBio product gets Japanese orphan drug status for CLL

Shionogi reports initial data from S-555739 trial in allergic rhinitis

FDA accepts NDA for Raptor Pharmaceuticals' nephropathic cystinosis drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...